Skip to main content

Table 2 Comparison of patient characteristics between remission and non-remission patients after 2 weeks of tacrolimus administration

From: Intravenous tacrolimus is a superior induction therapy for acute severe ulcerative colitis compared to oral tacrolimus

Whole tacrolimus Remission at 2 weeks Non-remission at 2 weeks p value
(N = 87) (N = 35) (N = 52)
Female/male 16 (46%)/19 (54%) 23 (44%)/29 (56%) 0.53
Age (years) 36 (23–54) 42 (28–50) 0.42
Disease duration (years) 4.0 (1.0–9.2) 2.7 (1.1–7.0) 0.75
Disease type: extensive/left-sided 31 (89%)/4 (11%) 40 (77%)/12 (23%) 0.14
Body mass index 19.4 (16.4–22.5) 19.6 (17.0–22.2) 0.77
Lichtiger index 13 (12–14) 13 (12–15) 0.81
Endoscopic score (UCEIS) 6 (5–7) 6 (4–8) 0.03
Hemoglobin (g/dL) 10.3 (10.0–12.7) 11.8 (9.5–13.1) 0.44
Albumin (g/dL) 3.2 (2.7–3.7) 3.3 (2.6–3.7) 0.85
C-reactive protein (mg/dL) 3.8 (0.9–10.2) 3.1 (1.6–7.6) 0.96
Erythrocyte sedimentation rate (mm/h) 48 (30–83) 54 (33–75) 0.93
Creatinine (mg/dL) 0.7 (0.6–0.8) 0.7 (0.6–0.8) 0.92
Corticosteroid refractory/dependent 23 (66%)/12 (34%) 43 (83%)/9 (17%) 0.06
Biologic agent naive 28 (80%) 33 (64%) 0.08
Intravenous tacrolimus 30 (86%) 35 (67%) 0.04
Decrease of Lichtiger index ≥ 3 points by day 3 21 (60%) 11 (21%) < 0.01
response at 1 week (LI decrease by 3 and less than 10) 32 (91%) 18 (35%) < 0.01
Tacrolimus concentration ≥ 10 ng/ml at day 1 21 (60%) 26 (50%) 0.24
Tacrolimus concentration ≥ 10 ng/ml at day 3 31 (89%) 42 (81%) 0.25
Adverse events 10 (29%) 8 (15%) 0.11
  1. Numerical data shows median value with interquartile range. Continuous variables were compared using the Mann–Whitney U test and categorical variables were compared using Fischer’s exact test
  2. UCEIS ulcerative colitis endoscopic index of severity